Scope Fluidics S.A.
ISIN: PLSCPFL00018 | Ticker: SCP | LEI: 259400EUNFX4E2BEHU15
Country: Poland
Scope Fluidics S.A. is a biotechnology company engaged in designing and developing innovative projects based on microfluidic technologies in medical diagnostics and healthcare.
Scope Fluidics S.A. owns a special-purpose vehicle, Bacteromic Sp. z o.o., established to develop the BacterOMIC system designed to assess the drug susceptibility of microorganisms.
In 2022, Scope Fluidics S.A. sold to Bio-Rad the technology of its proprietary PCR|ONE diagnostic system designed to assess the drug susceptibility of microorganisms as part of its special-purpose vehicle Curiosity Diagnostics Sp. z o.o.
2010
Served areaWorldwide
HeadquartersDuchnicka 3/16 Wej. A, 01-796 Warszawa – Poland
| Line item in (pln) | 02.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 52,733,000.00 | 346,155,000.00 |
| Noncurrent Assets | N/A | 7,034,000.00 | 9,464,000.00 |
| Property Plant And Equipment | N/A | 409,000.00 | 322,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 74,000.00 | 21,000.00 |
| Noncurrent Receivables | N/A | 159,000.00 | 655,000.00 |
| Current Assets | N/A | 45,699,000.00 | 336,691,000.00 |
| Inventories | N/A | 287,000.00 | 673,000.00 |
| Trade And Other Current Receivables | N/A | 1,177,000.00 | 4,420,000.00 |
| Cash and cash equivalents | 25,708,000.00 | 18,089,000.00 | 331,598,000.00 |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 19,553,000.00 | 336,691,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | 26,146,000.00 | 0.00 |
| Equity And Liabilities | N/A | 52,733,000.00 | 346,155,000.00 |
| Equity | 23,373,000.00 | 6,738,000.00 | 332,973,000.00 |
| Issued Capital | N/A | 269,000.00 | 273,000.00 |
| Retained Earnings | N/A | -57,260,000.00 | 261,229,000.00 |
| Share Premium | N/A | 63,729,000.00 | 71,471,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 6,738,000.00 | 332,973,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 |
| Liabilities | N/A | 45,995,000.00 | 13,182,000.00 |
| Noncurrent Liabilities | N/A | 17,277,000.00 | 8,233,000.00 |
| Noncurrent Government Grants | N/A | 3,455,000.00 | 3,689,000.00 |
| Deferred Tax Liabilities | N/A | 11,000.00 | 0.00 |
| Current Liabilities | N/A | 28,718,000.00 | 4,949,000.00 |
| Current Provisions For Employee Benefits | N/A | 933,000.00 | 1,177,000.00 |
| Other Shortterm Provisions | N/A | 313,000.00 | 634,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 305,000.00 | 525,000.00 |
| Other Current Payables | N/A | 7,000.00 | 16,000.00 |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 21,717,000.00 | 4,949,000.00 |
| Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 7,001,000.00 | 0.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 11,959,000.00 | 0.00 |
| Line item in (pln) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 0.00 | 404,000.00 |
| Raw Materials And Consumables Used | 656,000.00 | 872,000.00 |
| Services Expense | 3,033,000.00 | 5,016,000.00 |
| Wages And Salaries | 5,952,000.00 | 17,536,000.00 |
| Social Security Contributions | 466,000.00 | 802,000.00 |
| Depreciation And Amortisation Expense | 414,000.00 | 641,000.00 |
| Tax Expense Other Than Income Tax Expense | 54,000.00 | 0.00 |
| Other Expense By Nature | 173,000.00 | 358,000.00 |
| Profit Loss From Operating Activities | -10,249,000.00 | 393,328,000.00 |
| Finance Income | 11,000.00 | 12,611,000.00 |
| Finance Costs | 1,483,000.00 | 10,826,000.00 |
| Profit Loss Before Tax | -11,721,000.00 | 395,113,000.00 |
| Income Tax Expense Continuing Operations | 1,000.00 | 69,054,000.00 |
| Profit Loss From Continuing Operations | -11,722,000.00 | 326,059,000.00 |
| Profit Loss From Discontinued Operations | -4,913,000.00 | -7,570,000.00 |
| Profit (loss) | -16,635,000.00 | 318,489,000.00 |
| Profit Loss Attributable To Owners Of Parent | -16,635,000.00 | 318,489,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 |
| Line item in (pln) | 01.01.2022 | 02.01.2021 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | -16,635,000.00 | N/A | 318,489,000.00 |
| Adjustments For Decrease Increase In Inventories | 155,000.00 | N/A | -385,000.00 |
| Adjustments For Depreciation And Amortisation Expense | 414,000.00 | N/A | 664,000.00 |
| Adjustments For Provisions | 313,000.00 | N/A | 321,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | -51,000.00 | N/A | -418,122,000.00 |
| Other Adjustments To Reconcile Profit Loss | 508,000.00 | N/A | 0.00 |
| Cash Flows From Used In Operating Activities | -21,368,000.00 | N/A | -28,158,000.00 |
| Proceeds From Government Grants Classified As Investing Activities | 1,134,000.00 | N/A | 3,635,000.00 |
| Income Taxes Paid Refund Classified As Investing Activities | 0.00 | N/A | 72,025,000.00 |
| Cash Flows From Used In Investing Activities | -3,335,000.00 | N/A | 371,126,000.00 |
| Proceeds From Issuing Shares | 0.00 | N/A | 4,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 18,514,000.00 | N/A | 14,520,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 0.00 | N/A | 34,322,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 350,000.00 | N/A | 470,000.00 |
| Interest Paid Classified As Financing Activities | 0.00 | N/A | 10,042,000.00 |
| Cash Flows From Used In Financing Activities | 17,906,000.00 | N/A | -30,280,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -6,797,000.00 | N/A | 312,688,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 0.00 | N/A | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -6,797,000.00 | N/A | 312,688,000.00 |
| Cash and cash equivalents | 18,089,000.00 | 25,708,000.00 | 331,598,000.00 |
Please note that some sums might not add up.
PLSCPFL00018
LEI259400EUNFX4E2BEHU15
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.